Literature DB >> 24317317

Parkinson's disease biomarkers: resources for discovery and validation.

Mark Frasier1, Un Jung Kang.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24317317      PMCID： PMC3857671          DOI： 10.1038/npp.2013.246

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN： 0893-133X            Impact factor:   7.853


× No keyword cloud information.
  6 in total

Review 1.  Cerebrospinal fluid biomarkers in Parkinson disease.

Authors:  Lucilla Parnetti; Anna Castrioto; Davide Chiasserini; Emanuele Persichetti; Nicola Tambasco; Omar El-Agnaf; Paolo Calabresi
Journal:  Nat Rev Neurol       Date:  2013-02-19       Impact factor: 42.937

Review 2.  Proteomics of human cerebrospinal fluid: discovery and verification of biomarker candidates in neurodegenerative diseases using quantitative proteomics.

Authors:  A C Kroksveen; J A Opsahl; T T Aye; R J Ulvik; F S Berven
Journal:  J Proteomics       Date:  2010-11-25       Impact factor: 4.044

3.  DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease.

Authors:  Zhen Hong; Min Shi; Kathryn A Chung; Joseph F Quinn; Elaine R Peskind; Douglas Galasko; Joseph Jankovic; Cyrus P Zabetian; James B Leverenz; Geoffrey Baird; Thomas J Montine; Aneeka M Hancock; Hyejin Hwang; Catherine Pan; Joshua Bradner; Un J Kang; Poul H Jensen; Jing Zhang
Journal:  Brain       Date:  2010-02-15       Impact factor: 13.501

4.  Plasma epidermal growth factor levels predict cognitive decline in Parkinson disease.

Authors:  Alice S Chen-Plotkin; William T Hu; Andrew Siderowf; Daniel Weintraub; Rachel Goldmann Gross; Howard I Hurtig; Sharon X Xie; Steven E Arnold; Murray Grossman; Christopher M Clark; Leslie M Shaw; Leo McCluskey; Lauren Elman; Vivianna M Van Deerlin; Virginia M-Y Lee; Holly Soares; John Q Trojanowski
Journal:  Ann Neurol       Date:  2010-11-29       Impact factor: 10.422

Review 5.  The Parkinson Progression Marker Initiative (PPMI).

Authors: 
Journal:  Prog Neurobiol       Date:  2011-09-14       Impact factor: 10.885

6.  Preparation and application of monoclonal antibodies against oxidized DJ-1. Significant elevation of oxidized DJ-1 in erythrocytes of early-stage Parkinson disease patients.

Authors:  Yoshiro Saito; Takao Hamakubo; Yasukazu Yoshida; Yoko Ogawa; Yasuo Hara; Harutoshi Fujimura; Yasuharu Imai; Hiroko Iwanari; Yasuhiro Mochizuki; Mototada Shichiri; Keiko Nishio; Tomoya Kinumi; Noriko Noguchi; Tatsuhiko Kodama; Etsuo Niki
Journal:  Neurosci Lett       Date:  2009-09-03       Impact factor: 3.046
  6 in total
  2 in total

1.  Item Response Theory as an Efficient Tool to Describe a Heterogeneous Clinical Rating Scale in De Novo Idiopathic Parkinson's Disease Patients.

Authors:  Simon Buatois; Sylvie Retout; Nicolas Frey; Sebastian Ueckert
Journal:  Pharm Res       Date:  2017-07-10       Impact factor: 4.200

Review 2.  Precision medicine in Parkinson's disease patients with LRRK2 and GBA risk variants - Let's get even more personal.

Authors:  Christian U von Linstow; Ziv Gan-Or; Patrik Brundin
Journal:  Transl Neurodegener       Date:  2020-10-16       Impact factor: 8.014
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.